StreetInsider.com News Articles

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

The analyst comments "PRME announced a positive binding arbitration resolution with BEAM over PM647 in AATD, confirming PM647 is in PRME’s field with no monetary damages. This removes a key investor overhang and clears the path for a Q3:26 filing, with initial data in 2027. We continue to view PRME as undervalued for the platform’s potential. Buy. PRME announced a positive, binding resolution of its previously disclosed arbitration with Beam Therapeutics, with the tribunal declaring that PM647 falls within PRME’s “Field” under the companies’ 2019 Collaboration and

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

TD Cowen on Prime Medicine (PRME): 'We continue to view PRME as undervalued for the platform’s potential'

Wed, 08 Jul 2026 12:30:17 -0400

TD Cowen analyst Joseph Thome reiterated a Buy rating on Prime Medicine (NASDAQ: PRME).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst comments "The arbitration resolution (in favor of Prime Medicine, uncovered) in our view has limited impact to Beam as the ruling narrowly applies to PM647 rather than the overall prime editing estate. For context, Beam filed an AAA arbitration demand on April 16, 2025 alleging breach of the 2019 collaboration and license agreement, failure to transfer technical information, trade secret misappropriation and related business torts; Prime filed its own demand on April 18, 2025 seeking confirmation that its AATD

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

BofA Securities Comments on Beam Therapeutics Inc (BEAM) Amid Selloff

Wed, 08 Jul 2026 11:32:20 -0400

BofA Securities analyst Alec W. Stranahan reiterated a Buy rating and $47.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

H.C. Wainwright Reiterates Buy Rating on Beam Therapeutics Inc (BEAM)

Tue, 07 Jul 2026 07:03:46 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $80.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).

The analyst commented: "On June 30, we hosted a fireside chat with Beam's President Giuseppe Ciaramella, Ph.D., at H.C. Wainwright’s 4th Annual Cell Therapy Virtual Conference. Our fireside chat reinforced the two pillars of our investment thesis: risto-cel in sickle cell disease (SCD) and BEAM-302 in alpha-1 antitrypsin deficiency (AATD). On risto-cel, management is actively writing the biologics license application (BLA) and is on track to submit as early as the end of 2026, gated only on accumulating the final 15-month follow-up

Form 4 Beam Therapeutics Inc. For: Jun 30 Filed by: Simon Amy

Thu, 02 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26727526.html

Form 4 Beam Therapeutics Inc. For: Jun 30 Filed by: Simon Amy

Thu, 02 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260702/26727526.html

Form 4 Beam Therapeutics Inc. For: Jun 29 Filed by: Evans John M.

Wed, 01 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260701/26720598.html

Form 4 Beam Therapeutics Inc. For: Jun 29 Filed by: Evans John M.

Wed, 01 Jul 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260701/26720598.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Tue, 30 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260630/26713890.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Tue, 30 Jun 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260630/26713890.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706628.html

Form 144 Beam Therapeutics Inc. Filed by: Evans John M.

Mon, 29 Jun 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260629/26706628.html

Form 4 Beam Therapeutics Inc. For: Jun 25 Filed by: FMR LLC

Mon, 29 Jun 2026 14:17:00 -0400

si-local-file:///var/storage/secattach/20260629/26705500.html

Form 4 Beam Therapeutics Inc. For: Jun 25 Filed by: FMR LLC

Mon, 29 Jun 2026 14:17:00 -0400

si-local-file:///var/storage/secattach/20260629/26705500.html

Form 4 Beam Therapeutics Inc. For: Jun 17 Filed by: Ciaramella Giuseppe

Mon, 22 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260622/26672976.html

Form 4 Beam Therapeutics Inc. For: Jun 17 Filed by: Ciaramella Giuseppe

Mon, 22 Jun 2026 16:05:00 -0400

si-local-file:///var/storage/secattach/20260622/26672976.html

FDA clears Beam Therapeutics IND for PKU gene editing therapy

Thu, 18 Jun 2026 07:00:11 -0400

Beam Therapeutics Inc. (Nasdaq: BEAM) announced that the U.S. Food and Drug Administration has cleared its investigational new drug application for BEAM-304, a base editing therapy for phenylketonuria (PKU), a rare inherited metabolic disorder affecting approximately 20,000 people in the United States.

BEAM-304 is a liver-targeting lipid nanoparticle formulation designed to correct mutations in the phenylalanine hydroxylase gene that cause PKU. The therapy is delivered via intravenous infusion and aims to reduce toxic phenylalanine levels to within recommended guidelines while allowing patients to normalize their diet.

The company plans to initiate a Phase 1/2 open-label trial that will initially evaluate safety, tolerability,

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

Thu, 18 Jun 2026 07:00:00 -0400

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU

BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging FDA Guidance for Accelerated Development of Genome Editing Therapies

New Preclinical Data for BEAM-304 to be Presented at FASEB Genome Engineering: Research and Applications Conference

CAMBRIDGE, Mass., June 18, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has cleared the investigational

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

Thu, 18 Jun 2026 07:00:00 -0400

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU

BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging FDA Guidance for Accelerated Development of Genome Editing Therapies

New Preclinical Data for BEAM-304 to be Presented at FASEB Genome Engineering: Research and Applications Conference

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-304 for the Treatment of Phenylketonuria (PKU) by the United States (U.S.) Food and Drug Administration

Thu, 18 Jun 2026 07:00:00 -0400

BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU

BEAM-304 Program Designed as Platform-based Approach Reflecting Emerging FDA Guidance for Accelerated Development of Genome Editing Therapies

New Preclinical Data for BEAM-304 to be Presented at FASEB Genome Engineering: Research and Applications Conference